^Morris H, Wallach J (2014). „From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs”. Drug Testing and Analysis. 6 (7–8): 614—32. PMID24678061. doi:10.1002/dta.1620.
^Meyer MR, Orschiedt T, Maurer HH (фебруар 2013). „Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein”. Toxicology Letters. 217 (2): 137—42. PMID23273999. doi:10.1016/j.toxlet.2012.12.012.CS1 одржавање: Формат датума (веза)
^Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (октобар 2014). „Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS”. Drug Testing and Analysis. 6 (10): 1038—48. PMID24591097. doi:10.1002/dta.1621.CS1 одржавање: Формат датума (веза)
^Wink CS, Meyer GM, Meyer MR, Maurer HH (новембар 2015). „Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps”. Toxicology Letters. 238 (3): 39—44. PMID26276083. doi:10.1016/j.toxlet.2015.08.012.CS1 одржавање: Формат датума (веза)
